Repligen Corp (RGEN) stock
RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30144% above fair value
$170.29−2.38 (-1.38%)
Close on Nov 19, 2026Market cap $10.89BP/E –Yield –
Repligen pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Repligen's pe ratio was 234.5× on Nov 11, 2026, against 889.8× a year earlier. Over the last 5 years it ranged from 45.3× to 889.8×, with a median of 136.4×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 234.5× | −557.1 |
| 2024 | Oct 31, 2024 | 791.6× | +692.1 |
| 2023 | Dec 29, 2023 | 99.5× | +43.0 |
| 2022 | Dec 30, 2022 | 56.5× | −69.6 |
| 2021 | Dec 31, 2021 | 126.1× | −107.6 |
| 2020 | Dec 31, 2020 | 233.7× | +44.9 |
| 2019 | Dec 31, 2019 | 188.8× | +85.4 |
| 2018 | Dec 31, 2018 | 103.4× | +41.9 |
| 2017 | Dec 29, 2017 | 61.5× | −92.6 |
| 2016 | Dec 30, 2016 | 154.1× | +49.3 |
| 2015 | Dec 31, 2015 | 104.8× | +49.8 |
| 2014 | Dec 31, 2014 | 55.0× | – |
See a number that looks wrong?